LUTS pharmacotherapy: Any news?

**Location:** Room 14a (ICM, Level 1)

**Chairs:** A. Ergen, Ankara (TR)
R. Umbas, Jakarta (ID)
A. Sahai, London (GB)

**Aims and objectives of this presentation**
Basic and clinical news from the wide field of LUTS pharmacotherapy will be covered during this session

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

**867**
**Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: A randomized, prospective, comparative trial using a urodynamic study**
By: Matsukawa Y., Takai S., Fujita T., Majima T., Kato M., Yamamoto T., Gotoh M.
**Institutes:** Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan

**868**
**Dutasteride in combination with imidafenacin versus dutasteride alone for management of benign prostatic enlargement with overactive bladder: A multicenter, randomized controlled trial**
By: Yamanishi T., Asakura H., Seki N., Tokunaga S.
**Institutes:** Dokkyo Medical University, Dept. of Urology, Continence Center, Tochigi, Japan,
Saitama Medical University Hospital, Dept. of Urology, Saitama, Japan,
Kyushu Central Hospital, Dept. of Urology, Fukuoka, Japan,
Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

**869**
**Effects of withdrawing the alpha-1 blocker from alpha-1 blocker plus 5-alpha-reductase inhibitor combination therapy on patients with benign prostatic hyperplasia from the perspective of urodynamic study**
By: Matsukawa Y., Funahashi Y., Matsu K., Ishida S., Yoshino Y., Yamamoto T., Gotoh M.
**Institutes:** Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan

**871**
**Surgical outcome of BPH patients with storage symptoms requiring antimuscarinics before surgery – a nationwide population-based study**
**Institutes:** Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

**872**
**Cardiovascular (CV) assessments in a randomized, double-blind, phase 3b trial of mirabegron add-on treatment in incontinent overactive bladder (OAB) patients with an inadequate response to solifenacin monotherapy**
**Institutes:** University of Bristol, Bristol Urological Institute, Bristol, United Kingdom,
Royal Hallamshire Hospital, Sheffield Hallam University, Sheffield, United Kingdom,
Dokuz Eylül University School of Medicine, Dept. of Urology, Izmir, Turkey,
University of Athens Medical School, Dept. of Urology, Athens, Greece,
Hospital Universitario Infantia Leonor, Madrid, Spain,
St Elizabeths Medical Center, Brighton, Massachusetts, United States of America,
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada,
Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom,
Astellas Pharma Global Development, Leiden, The Netherlands,
Alliance Urology Specialists, Greensboro, North Carolina, United States of America
Tadalafil improves storage dysfunction via increase in bladder blood flow and suppression of ATP release from the urothelium in metabolic syndrome rats
By: Zha X., Ito H., Aoki Y., Matsuta Y., Yamaguchi H., Yokoyama O.
Institutes: Faculty of Medical Science, University Of Fukui, Dept. of Urology, Yoshida-gun, Japan

Alpha1-adrenoceptor antagonist ameliorates memory impairment in the patient with LUTS? A study about the influence of tamsulosin on the memory impairment through enhancement of alpha1A-adrenoceptor in the hippocampus of old-aged rats
Institutes: 1The Catholic University of Korea, Kangnam St. Mary’s Hospital, Dept. of Urology, Seoul, South Korea, 2Gachon University Gil Medical Center, Gachon University School of Medicine, Dept. of Urology, Incheon, South Korea, 3Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

Evaluation of tamsulosin therapy in the treatment of indwelling double–J stent related discomfort
By: Moussa A., Mohammed H., Abd-Bary A., Gaber A., El-Dessouky A., Masoud, A.
Institutes: Beni Suef University, Dept. of Urology, Beni Suef, Egypt

Role of silodosin in decreasing lower urinary tract and sexual problems in male patients with double J ureteral stents
By: Hussein H.A.1, Shaker H.2, Fathy H.1, Sheeba M.1, Abdelazim M.S.1, Bedair A.S.2, Aly A.H.1
Institutes: 1Cairo University, Dept. of Urology, Cairo, Egypt, 2Fayoum University, Dept. of Urology, Fayoum, Egypt

The efficacy and safety of onabotulinumtoxinA and solifenacin compared to placebo in solifenacin-naïve patients with idiopathic overactive bladder: Results from a multicentre, randomised, double-blind, phase 3b trial
By: Everaert K.1, Sriram R.2, Kohan A.3, Aliotta P.4, Mc Cammon K.5, Abrams S.6, Lam W.7, Herschorn S.8
Institutes: 1Ghent University Hospital, Dept. of Urology, Ghent, Belgium, 2University Hospital Coventry, Dept. of Urology, Coventry, United Kingdom, 3Advanced Urology Centers of New York, Dept. of Urology, Bethpage, United States of America, 4Western New York Urology Associates, Dept. of Urology, Williamsville, United States of America, 5Eastern Virginia Medical School, Dept. of Urology, Norfolk, United States of America, 6Allergan Plc, Dept. of Urology, Irvine, United States of America, 7Allergan Plc, Dept. of Biostatistics, Irvine, United States of America, 8University of Toronto, Dept. of Urology, Toronto, Canada

Licensed and approved vs traditional dose of onabotulinumtoxinA in refractory overactive bladder?
By: Eldred-Evans D.1, Seth J.1, Dowson C.2, Malde S.3, Watkins J.1, Khan M.S.1, Dasgupta P.1, Sahai A.1
Institutes: 1Guy’s and St Thomas’ Nhs Trust, Pelvic floor unit, London, United Kingdom, 2Guy’s and St Thomas’ Nhs Trust, Dept. of Urology, London, United Kingdom, 3University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

Preoperative serum C-reactive protein in patients with pelvic organ prolapse is a predictor of de novo overactive bladder
By: Tomohiro M., Ohba K., Yasuda T., Asai A., Miyata Y., Sakai H.
Institutes: Nagasaki University School of Medicine, Dept. of Urology, Nagasaki, Japan

Summary and context
A. Sahai, London (GB)